AngioDynamics (STU:UG2) Tariff Resilience Score: 7/10 (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:UG2 AngioDynamics Inc STU:UG2
66 GF Score
Price €11.80
GF Value €8.32
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is AngioDynamics Tariff Resilience Score?

AngioDynamics STU:UG2 -3.28% 66 Tariff Resilience Score is 7 as of Jul. 18, 2026. GuruFocus rates STU:UG2 with a GF Score™ of 66/100 and a GF Value™ of €8.32 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 834 Medical Devices & Instruments companies, AngioDynamics ranks better than 98.08% on this metric.

AngioDynamics has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

AngioDynamics has AngioDynamics, a medical device company, faces moderate tariff exposure. While medical devices can be subject to tariffs, the company benefits from exemptions and has diversified its supply chain to mitigate risks.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes AngioDynamics might have Highly Resilient.

AngioDynamics  (STU:UG2) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

AngioDynamics Tariff Resilience Score Related Terms

STU:UG2 vs NNNN, OSUR, UTMD: Tariff Resilience Score Comparison

For the Medical Instruments & Supplies subindustry, AngioDynamics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AngioDynamics Tariff Resilience Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AngioDynamics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where AngioDynamics's Tariff Resilience Score falls into.


STU:UG2
66GF Score
AngioDynamics Inc STU:UG2
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
AngioDynamics (STU:UG2) has a Tariff Resilience Score of 7 as of Jul. 18, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, AngioDynamics ranks #16 out of 834 companies in the Medical Devices & Instruments industry, placing it in the top 1.9%.
Is AngioDynamics' Tariff Resilience Score too high?
AngioDynamics' current Tariff Resilience Score is 7. Based on the distribution chart, AngioDynamics ranks #16 out of 834 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, AngioDynamics has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AngioDynamics' Tariff Resilience Score compare to NNNN and OSUR?
According to the Medical Devices & Instruments industry distribution chart, AngioDynamics ranks #16 out of 834 companies for Tariff Resilience Score. This places AngioDynamics in the top 2% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Medical Devices & Instruments company?
A good Tariff Resilience Score depends on the Medical Devices & Instruments industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. AngioDynamics's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AngioDynamics stock overvalued right now?
Based on GuruFocus' analysis, AngioDynamics (STU:UG2) is currently considered Significantly Overvalued. The stock's GF Value™ is €8.32, compared to a current price of €11.80 — trading 41.8% above its estimated fair value. The current Tariff Resilience Score is 7. AngioDynamics' overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For AngioDynamics (STU:UG2), the current Tariff Resilience Score is 7 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AngioDynamics (STU:UG2) Overvalued in 2026?

Based on GuruFocus' analysis, AngioDynamics stock appears to be overvalued. The current stock price of €11.80 is trading 41.8% above its estimated GF Value™ of €8.32. GuruFocus considers AngioDynamics to be Significantly Overvalued.

Key valuation signals for STU:UG2:

  • Tariff Resilience Score: 7
  • GF Value™: €8.32 vs. price of €11.80 (41.8% above fair value)
  • GF Score™: 66/100 with 6 warning signs

No single metric tells the full story. See the STU:UG2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AngioDynamics Business Description

Other Exchanges ANGO:USA
Address 14 Plaza Drive, Latham, NY, USA, 12110
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
66GF Score

Get the complete analysis for STU:UG2

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.80
Price
€8.32
GF Value